HLS Therapeutics Inc. provided consolidated earnings guidance for the fiscal year 2024. for the year, the company expects consolidated revenue of $63.5 million-66.5 million, or 1%-5% growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.73 CAD | -0.84% | +1.72% | +19.75% |
08/04 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
14/03 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.75% | 110M | |
+17.88% | 71.72B | |
-1.07% | 24.29B | |
+8.01% | 8.31B | |
-18.28% | 8.22B | |
+2.69% | 8.16B | |
+4.40% | 4.76B | |
+16.55% | 4.31B | |
-0.70% | 4.1B | |
-2.20% | 3.91B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024